研究者詳細 - 松本　准

論文 - 松本　准

分割表示 24 件中 1 - 20 件目／全件表示 >>

学習システムKimBen pharmaの薬学教育への導入と取り組みのアンケート調査について査読

東恩納司, 武田達明, 松本准, 小山敏広, 岩田直大, 蔵田靖子, 濱野裕章, 座間味義人

医薬品情報学 26 ( 4 ) 173 - 177 2025年

Precision medicine for patients with renal cell carcinoma based on drug-metabolizing enzyme expression levels 招待査読

Jun Matsumoto

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 145 ( 1 ) 7 - 14 2025年

Comprehensive analysis of adverse event profile changes with pertuzumab addition to trastuzumab-based breast cancer therapy: disproportionality analysis using VigiBase 査読

Tatsuaki Takeda, Jun Matsumoto, Tomonori Sakai, Naohiro Iwata, Hirofumi Hamano, Toshihiro Koyama, Noritaka Ariyoshi, Yoshito Zamami

British Journal of Clinical Pharmacology 2025年

A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases 査読

Tatsuaki Takeda, Shiho Sugimoto, Jun Matsumoto, Naohiro Iwata, Akihiko Nakamoto, Aya Fukuma Ozaki, Hirofumi Hamano, Noritaka Ariyoshi, Yoshito Zamami

International Journal of Clinical Pharmacy 46 ( 2 ) 536 - 541 2024年

Adverse Events of Nivolumab plus Ipilimumab versus Nivolumab plus Cabozantinib: A Real-World Pharmacovigilance Study 査読

Yurie Oka, Jun Matsumoto, Tatsuaki Takeda, Naohiro Iwata, Takahiro Niimura, Aya Fukuma Ozaki, Kensuke Bekku, Hirofumi Hamano, Motoo Araki, Keisuke Ishizawa, Yoshito Zamami, Noritaka Ariyoshi

International Journal of Clinical Pharmacy 46 ( 3 ) 745 - 750 2024年

Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System 査読国際誌

Jun Matsumoto, Naohiro Iwata, Shogo Watari, Soichiro Ushio, Shoya Shiromizu, Tatsuaki Takeda, Hirofumi Hamano, Makoto Kajizono, Motoo Araki, Yasutomo Nasu, Noritaka Ariyoshi, Yoshito Zamami

European Urology Focus 9 ( 1 ) 141 - 144 2023年

Significance of UGT1A6, UGT1A9, and UGT2B7 genetic variants and their mRNA expressions in the clinical outcome of renal cell carcinoma 査読国際誌

Jun Matsumoto, Anzu Nishimoto, Shogo Watari, Hideo Ueki, Shoya Shiromizu, Naohiro Iwata, Tatsuaki Takeda, Soichiro Ushio, Makoto Kajizono, Masachika Fujiyoshi, Toshihiro Koyama, Motoo Araki, Koichiro Wada, Yoshito Zamami, Yasutomo Nasu, Noritaka Ariyoshi

Molecular and Cellular Biochemistry 478 ( 8 ) 1779 - 1790 2023年

担当区分：筆頭著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

UDP-glucuronosyltransferase (UGT) metabolizes a number of endogenous and exogenous substrates. Renal cells express high amounts of UGT; however, the significance of UGT in patients with renal cell carcinoma (RCC) remains unknown. In this study, we profile the mRNA expression of UGT subtypes (UGT1A6, UGT1A9, and UGT2B7) and their genetic variants in the kidney tissue of 125 Japanese patients with RCC (Okayama University Hospital, Japan). In addition, we elucidate the association between the UGT variants and UGT mRNA expression levels and clinical outcomes in these patients. The three representative genetic variants, namely, UGT1A6 541A > G, UGT1A9 i399C > T, and UGT2B7-161C > T, were genotyped, and their mRNA expression levels in each tissue were determined. We found that the mRNA expression of the three UGTs (UGT1A6, UGT1A9, and UGT2B7) are significantly downregulated in RCC tissues. Moreover, in patients with RCC, the UGT2B7-161C > T variant and high UGT2B7 mRNA expression are significantly correlated with preferable cancer-specific survival (CSS) and overall survival (OS), respectively. As such, the UGT2B7-161C > T variant and UGT2B7 mRNA expression level were identified as significant independent prognostic factors of CSS and CSS/OS, respectively. Taken together, these findings indicate that UGT2B7 has a role in RCC progression and may, therefore, represent a potential prognostic biomarker for patients with RCC.

DOI： 10.1007/s11010-022-04637-4

PubMed

researchmap

Awareness about the Establishment of Clinical Evidence among Community Pharmacists: A Large-scale Survey among Members of the Okayama Pharmaceutical Association. 査読

Jun Matsumoto, Madoka Itano, Naohiro Iwata, Masafumi Oro, Chikako Kitakaze, Ayuko Hirota, Katsuhiko Makino, Tomoyuki Tateno, Ryohei Terai, Hideo Kenmotsu, Motohide Date

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 143 ( 4 ) 393 - 404 2023年

担当区分：筆頭著者,　責任著者記述言語：日本語掲載種別：研究論文（学術雑誌）

Community pharmacists in Japan participate in many important clinical cases involving drug therapies. This involvement should be researched and widely publicized to promote evidence-based medicine (EBM). However, the awareness level about the establishment of clinical evidence among community pharmacists remains unknown. Therefore, this large-scale questionnaire survey was conducted among members of the Okayama Pharmaceutical Association to clarify the awareness about the establishment of clinical evidence among community pharmacists to determine the major factors affecting their awareness. Questionnaires requiring open-ended responses were developed in Google Forms. Finally, 366 valid answers were obtained and statistically analyzed based on three aspects: academic conference presentation, research article publication, and research conduct. More than 50% of the participants agreed that they must engage in the establishment of clinical evidence. However, they were unwilling to engage in it by themselves. Additionally, the awareness about the establishment of clinical evidence among participants aged <40 years, who underwent a 6-year course, and with presentation experience was greater than that among participants aged ≥40 years, who underwent a 4-year course and without presentation experience. Thus, age, course duration, and presentation experience are important factors influencing awareness about the establishment of clinical evidence. Further, >70% of the participants did not have enough time to engage in the establishment of clinical evidence, suggesting that reducing workload and ensuring adequate time are necessary for such engagements. Our novel findings may increase the establishment of clinical evidence by community pharmacists, improve community pharmacists' social standing, and promote EBM in Japan.

DOI： 10.1248/yakushi.22-00151

PubMed

researchmap

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination 査読

Takahiro Niimura, Mitsuhiro Goda, Koji Miyata, Jun Matsumoto, Toshihiko Yoshioka, Hirofumi Hamano, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami, Keisuke Ishizawa

Frontiers in Drug Safety and Regulation 3 1 - 8 2023年

Proton pump inhibitors and rhabdomyolysis: analysis of two different cross-sectional databases 査読

Satoru Mitsuboshi, Hirofumi Hamano, Yurika Kunki, Takahiro Niimura, Masayuki Chuma, Soichiro Ushio, Tsung-Jen Lin, Jun Matsumoto, Tatsuaki Takeda, Makoto Kajizono, Yoshito Zamami, Keisuke Ishizawa

Annals of Pharmacotherapy 57 ( 11 ) 1255 - 1263 2023年

掲載種別：研究論文（学術雑誌）

Background: It is unclear whether use of a proton pump inhibitors (PPIs) increases the risk of rhabdomyolysis. Objective: To clarify whether use of PPIs increases the risk of rhabdomyolysis. Methods: This cross-sectional study analyzed data entered into the Medical Data Vision (MDV) database in Japan and into the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). The MDV data were analyzed to evaluate the association between use of PPIs and rhabdomyolysis. Then, the FAERS data were analyzed to evaluate whether the risk of rhabdomyolysis was increased further when a statin or fibrate was used concomitantly with a PPI. In both analyses, histamine-2 receptor antagonist was set as a comparator because it is used to treat gastric disease. In the MDV analysis, Fisher’s exact test and multiple logistic regression analysis were performed. In the FAERS analysis, a disproportionality analysis using Fisher’s exact test and multiple logistic regression analysis were performed. Results: Multiple logistic regression analysis of both databases showed a significant association between use of PPIs and an increased risk of rhabdomyolysis (odds ratio [OR] = 1.74-1.95, P ≤ 0.01). However, use of a histamine-2 receptor antagonist was not significantly associated with increased risk of rhabdomyolysis. In the sub-analysis of the FAERS data, use of a PPI did not increase the risk of rhabdomyolysis in patients receiving a statin. Conclusion and Relevance: The data in 2 separate databases consistently suggest that PPIs may increase the risk of rhabdomyolysis. The evidence for this association should be assessed in further drug safety studies.

DOI： 10.1177/10600280231156270

Scopus

PubMed

researchmap

パンデミック後の薬学部病院実務実習の変化

猪田宏美, 武田達明, 西原茂樹, 松本准, 有吉範高, 座間味義人

医学教育 54 ( 6 ) 649 - 650 2023年

Relevance of CYP3A5 expression on the clinical outcome of patients with renal cell carcinoma 査読国際誌

Jun Matsumoto, Yumi Kotera, Shogo Watari, Koichi Takeuchi, Hideo Ueki, Toshihiro Koyama, Koichiro Wada, Masachika Fujiyoshi, Yasutomo Nasu, Noritaka Ariyoshi

Anticancer Research 41 ( 5 ) 2511 - 2521 2021年

担当区分：筆頭著者記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND/AIM: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC). PATIENTS AND METHODS: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined. RESULTS: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival. CONCLUSION: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC.

DOI： 10.21873/anticanres.15029

PubMed

researchmap

Blood concentration of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: correlation with cytochrome P450 gene polymorphisms 査読国際誌

Shogo Watari, Motoo Araki, Jun Matsumoto, Kasumi Yoshinaga, Takanori Sekito, Yumi Murayama, Yosuke Mitsui, Takuya Sadahira, Risa Kubota, Shingo Nishimura, Koichiro Wada, Yasuyuki Kobayashi, Hidemi Takeuchi, Katsuyuki, Tanabe, Masashi Kitagawa, Hiroshi Morinaga, Shinji Kitamura, Hitoshi Sugiyama, Noritaka Ariyoshi, Jun Wada, Masami Watanabe, Toyohiko Watanabe, Yasutomo Nasu

Drug Metabolism and Pharmacokinetics 40 100407 2021年

Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir 査読国際誌

Jun Matsumoto, Su Nwe San, Masachika Fujiyoshi, Ayano Kawauchi, Natsumi Chiba, Ran Tagai, Ryoko Sanbe, Shiho Yanaka, Hiroaki Sakaue, Yoshinori Kato, Hiroyoshi Nakamura, Harumi Yamada, Noritaka Ariyoshi

Journal of Human Genetics 65 ( 4 ) 143 - 153 2020年

コロナ禍における薬学実務実習での工夫査読

猪田宏美, 藤吉正哉, 西原茂樹, 松本准, 有吉範高, 千堂年昭

医学教育 51 ( 5 ) 541 - 543 2020年

Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro 査読国際誌

Su Nwe San, Jun Matsumoto, Masako Koike, Yumi Saito, Hiroaki Sakaue, Yoshinori Kato, Masachika Fujiyoshi, Noritaka Ariyoshi, Harumi Yamada

Xenobiotica 49 ( 8 ) 935 - 944 2019年

A proposed simple screening method to determine relative contributions of CYP3A4 and CYP3A5 to drug metabolism in vitro 査読

Jun Matsumoto, Hiroyoshi Nakamura, Su Nwe San, Hikari Sato, Manami Takezawa, Ryuto Kishi, Yutaro Kito, Junko Sugano, Mai Izuki, Nao Yanagisawa, Naoki Ikeda, Yusuke Saito, Yoshinori Kato, Harumi Yamada, Masachika Fujiyoshi, Noritaka Ariyoshi

Personalized Medicine Universe 8 41 - 44 2019年

Determination of sofosbuvir via a high-performance liquid chromatography method using ultraviolet detection 査読

Su Nwe San, Jun Matsumoto, Masako Koike, Yumi Saito, Hiroaki Sakaue, Yoshinori Kato, Noritaka Ariyoshi, Harumi Yamada

Journal of International University of Health and Welfare 23 ( 1 ) 130 - 136 2018年

Linezolid-Induced Thrombocytopenia Is Caused by Suppression of Platelet Production via Phosphorylation of Myosin Light Chain 2 査読

Masataka Tajima, Yoshinori Kato, Jun Matsumoto, Iori Hirosawa, Mariko Suzuki, Yuki Takashio, Mao Yamamoto, Yoshifumi Nishi, Harumi Yamada

Biological and Pharmaceutical Bulletin 39 ( 11 ) 1846 - 1851 2016年11月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：PHARMACEUTICAL SOC JAPAN

Linezolid (LZD) is an antimicrobial that is commonly used for treatment of vancomycin-resistant Enterococci and methicillin-resistant Staphylococcus aureus infections. However, the development of thrombocytopenia, one of the most frequent adverse side effects of this antimicrobial, can lead to discontinuation of LZD treatment. While clinical studies indicate that risk factors for the development of LZD-induced thrombocytopenia include treatment for >14 consecutive days, renal dysfunction, and chronic liver disease, the fundamental mechanism governing the pathogenesis of this disorder remains unclear. In this study, we aimed to elucidate the mechanism of LZD-induced thrombocytopenia by investigating the impact of LZD treatment on platelet destruction and production using rat platelet-rich plasma (PRP) and human immortalized cell lines, respectively. Compared to the control population, an increase in lactate dehydrogenase release was not detected upon exposure of rat PRP to varying concentrations of LZD, indicating that this compound is not cytotoxic towards platelets. Meanwhile, LZD treatment resulted in a significant dose-dependent increase in the proliferation of HEL human erythroleukemia and MEG-01 human megakaryoblast cells in vitro, but did not influence the differentiation of these cell lines. Lastly, LZD treatment yielded elevated levels of phosphorylation of myosin light chain 2 (MLC2), which regulates platelet release, in MEG-01 cells. Based on these results, we speculate that LZD induces thrombocytopenia by promoting MLC2 phosphorylation and thereby suppressing the release of platelets from mature megakaryocytes. These findings provide the first insight into the mechanism of LZD-mediated thrombocytopenia and may facilitate the development of strategies to treat and/or prevent this disease.

DOI： 10.1248/bpb.b16-00427

Web of Science

researchmap

Organic anion transporting polypeptide 2B1 expression correlates with uptake of estrone-3-sulfate and cell proliferation in estrogen receptor-positive breast cancer cells 査読

Jun Matsumoto, Noritaka Ariyoshi, Masahiro Sakakibara, Takeo Nakanishi, Yoshiyuki Okubo, Nobumitsu Shiina, Kaoru Fujisaki, Takeshi Nagashima, Yukio Nakatani, Ikumi Tamai, Harumi Yamada, Hiroshi Takeda, Itsuko Ishii

Drug Metabolism and Pharmacokinetics 30 ( 2 ) 133 - 141 2015年4月

担当区分：筆頭著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：JAPANESE SOC STUDY XENOBIOTICS

Estrone-3-sulfate (E1S) is thought to be a major estrogen precursor in estrogen receptor (ER)-positive breast cancer. Since E1S is a hydrophilic compound, the uptake of E1S into cancer cells is probably mediated by transporters, such as organic anion-transporting polypeptide (OATP, SLCO) family. In this study, we investigated the relationship between expression of OATP2B1 and cell proliferation in ER-positive breast cancer. Cell-based assays were carried out in MCF-7 cells both with and without overexpression of OATP2B1. Normal breast and tumor tissues were collected and used in this study. Cell proliferation, ER-mediated transcriptional activities and estradiol secretion were stimulated by addition of E1S to the culture medium of MCF-7 cells. These stimulatory effects were significantly greater in MCF-7 cells overexpressing OATP2B1 than in control cells. The expression level of SLCO2B1 mRNA was significantly correlated with histological grade, Ki-67 labelling index and mRNA expression of steroid sulfatase. The expression level of SLCO2B1 mRNA in luminal B-like cancers was higher than that in luminal A-like cancers. Uptake of E1S resulted in down-regulation of ER alpha protein and induction of Ki-67 in MCF-7 cells. The present study suggests that OATP2B1 is involved in cell proliferation by increasing the amount of estrogen in ER-positive breast cancer cells. Copyright (C) 2014, The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.

DOI： 10.1016/j.dmpk.2014.10.005

Web of Science

researchmap

　前のページ - 次のページ　

<松本 准>

論文 - 松本 准

<松本　准>

論文 - 松本　准